Role of Left Ventricular Pacing Site
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Cardiac resynchronization therapy has been shown to be effective in reducing symptoms and mortality in heart failure patients. However, very few is known about the importance of the left ventricular pacing site. We study in a random order 11 different left ventricular pacing sites and compare their hemodynamics using pressure-volume catheters. The consequences on the surface ECG are also assessed.
| Condition | Intervention |
|---|---|
|
Heart Failure Cardiomyopathy, Dilated Coronary Disease |
Device: left ventricular pacing |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Single Blind Primary Purpose: Treatment |
| Official Title: | Importance of Left Ventricular Pacing Site in Biventricular Resynchronization Therapy for Severe Heart Failure |
- Variation in left ventricular dp/dt max
- pressures and volumes of the left ventricle
- stroke work
- surface ECG repolarisation
| Estimated Enrollment: | 33 |
| Study Start Date: | November 2003 |
| Estimated Study Completion Date: | December 2007 |
Background. Cardiac resynchronization therapy has been shown to be effective in reducing symptoms and mortality in heart failure patients. However, very few is known about the importance of the left ventricular pacing site.
Design. Single-blind, monocentric, randomized cross-over study comparing 11 left ventricular pacing sites in a random order.
Intervention. Left ventricular DDD pacing on 11 ventricular sites, prior to the implantation. At each pacing site, a control hemodynamics will be obtained in AAI pacing at the same pacing rate. At each pacing site, 2 AV delays, a short and a long one, will be assessed.
Eligibility criteria. Patients referred for cardiac resynchronization therapy for heart failure
Outcomes. Hemodynamic measures using pressure-volume catheters.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Heart failure referred for cardiac resynchronization therapy
- NYHA Class III or IV
- Informed consent form signed
Exclusion Criteria:
- Hypertension not controlled by treatment
- Coronary ischemia not controlled by treatment
Contacts and Locations| Contact: Pierre Jaïs, Dr | 33 (0) 5 57 65 64 71 | pierre.jais@chu-bordeaux.fr |
| France | |
| Hôpital Cardiologique du Haut Lévêque, Rythmology department, Pr CLEMENTY, 3rd Floor | Recruiting |
| Pessac, France, 33604 | |
| Contact: Pierre Jaïs, Dr 33 (0) 5 57 65 64 71 pierre.jais@chu-bordeaux.fr | |
| Principal Investigator: Pierre Jaïs, Dr | |
| Principal Investigator: | Pierre Jaïs, Dr | University Hospital, Bordeaux |
| Study Chair: | Paul Perez, Dr | University Hospital, Bordeaux |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00221780 History of Changes |
| Other Study ID Numbers: | 9426-01, 2001-030 |
| Study First Received: | September 13, 2005 |
| Last Updated: | June 28, 2007 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by University Hospital, Bordeaux:
|
Heart failure Cardiomyopathy, dilated Coronary disease Cardiac Pacing, Artificial |
Hemodynamics Randomized Controlled Trials Single-Blind Study |
Additional relevant MeSH terms:
|
Cardiomyopathy, Dilated Coronary Disease Coronary Artery Disease Heart Failure Cardiomyopathies Cardiomegaly |
Heart Diseases Cardiovascular Diseases Myocardial Ischemia Vascular Diseases Arteriosclerosis Arterial Occlusive Diseases |
ClinicalTrials.gov processed this record on May 19, 2013